Lampalizumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Lampalizumab
Monoclonal antibody
Type Fab fragment
Source Humanized (from mouse)
Target CFD
Clinical data
Legal status
  • Phase 3
Routes of
administration		 Intravitreal
Identifiers
CAS Number 1278466-20-8
ATC code none
IUPHAR/BPS 8294
Chemical data
Formula C2068H3214N546O676S13
Molecular mass 46.96 kg/mol

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.[1][2]

Enrollment in Phase 3 clinical trials has been initiated.[3] Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.[4]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
  3. ↑ Roche starts Phase III trials of lampalizumab, PharmaTimes
  4. ↑ [1], "NIH - US National Library of Medicine"


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Lampalizumab&oldid=707384325"